SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.

Sarafidis, Pantelis and Ferro, Charles J and Morales, Enrique and Ortiz, Alberto and Malyszko, Jolanta and Hojs, Radovan and Khazim, Khaled and Ekart, Robert and Valdivielso, Jose and Fouque, Denis and London, Gérard M and Massy, Ziad and Ruggenenti, Petro and Porrini, Esteban and Wiecek, Andrej and Zoccali, Carmine and Mallamaci, Francesca and Hornum, Mads (2019) SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 34 (2). pp. 208-230. ISSN 1460-2385.

Full text not available from this repository.
Official URL: https://academic.oup.com/ndt/article/34/2/208/5307...

Abstract

Chronic kidney disease (CKD) in patients with diabetes mellitus (DM) is a major problem of public health. Currently, many of these patients experience progression of cardiovascular and renal disease, even when receiving optimal treatment. In previous years, several new drug classes for the treatment of type 2 DM have emerged, including inhibitors of renal sodium-glucose co-transporter-2 (SGLT-2) and glucagon-like peptide-1 (GLP-1) receptor agonists. Apart from reducing glycaemia, these classes were reported to have other beneficial effects for the cardiovascular and renal systems, such as weight loss and blood pressure reduction. Most importantly, in contrast to all previous studies with anti-diabetic agents, a series of recent randomized, placebo-controlled outcome trials showed that SGLT-2 inhibitors and GLP-1 receptor agonists are able to reduce cardiovascular events and all-cause mortality, as well as progression of renal disease, in patients with type 2 DM. This document presents in detail the available evidence on the cardioprotective and nephroprotective effects of SGLT-2 inhibitors and GLP-1 analogues, analyses the potential mechanisms involved in these actions and discusses their place in the treatment of patients with CKD and DM.

Item Type: Article
Subjects: WK Endocrine system. Endocrinology
Divisions: Emergency Services > Renal
Related URLs:
Depositing User: Mr Philip O'Reilly
Date Deposited: 18 Mar 2019 14:52
Last Modified: 18 Mar 2019 14:52
URI: http://www.repository.heartofengland.nhs.uk/id/eprint/1931

Actions (login required)

View Item View Item